Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...

Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore O’Neill ...

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...

The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death.

A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best stocks for 20 years. On February 12, CRISPR Therapeutics announced its ...

Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...

If you are wondering whether CRISPR Therapeutics at around US$48.75 is a bargain or a concern, the key question is how its current share price lines up with what the business may be worth. The stock ...

Co‑injecting three common amino acids with LNPs dramatically boosted both mRNA delivery and CRISPR gene editing efficiency in preclinical models.

CRISPR Therapeutics AG CRSP shares moved lower Tuesday after the biotechnology company outlined plans to raise capital ...

Lipid nanoparticles, or LNPs, best known as the delivery vehicle for the COVID-19 mRNA vaccines received by billions of people, are now at the center of a much larger medical revolution. Researchers ...

One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand treatment to others.